Mylan Faces Another Class Action Lawsuit Over EpiPen Pricing

Mylan has been in the news a lot lately, and now that it’s facing a “new proposed class action lawsuit over the price of its EpiPen allergy treatment,” the company is bound to be in the news even more in coming months. The lawsuit was filed by three EpiPen purchasers on Monday in Tacoma, Washington federal court, claiming that “Mylan engaged in a scheme with pharmacy benefit managers (PBMs).” What are PBMs? They’re “companies that act as intermediaries between pharmacies, insurers and drug companies – to dominate the market and overcharge consumers.”




Cheaper Healthcare: Waste Not, Want Less

While President Trump might not have realized how complex fixing healthcare could be, pretty much everyone else had some idea. What people may not fully realize is that the private sector isn’t as virtuously free of the kinds of waste, fraud, and abuse that are typically attributed only to government. Putting a dent in these money pits would go a long way towards bringing cheaper healthcare to desperate people.


Drug Copay Clawbacks are a Silent Scam

How many people are scammed every day by drug copay clawbacks? When you take your doctor’s prescription to a pharmacy to be filled, you’re probably thinking mostly of your health. However, behind the scenes, questionable pricing practices may take advantage of people who want to stay healthy or get better when they’re sick.


Lawsuit Filed Against Major Insulin Manufacturers Accused of Fixing Prices

Insulin is one of those medications that is absolutely necessary for the continued health of millions of Americans. In fact, about six million of the 29 million Americans who live with diabetes require insulin just to stay alive. Unfortunately, the price for this precious medication has shot up in price over recent years. Between 2002 and 2013 alone, insulin prices “more than tripled, to more than $700 per patient.” Fortunately for consumers, we may see an end to these dramatic price hikes because a federal lawsuit has been filed against the three big insulin manufacturers, accusing them of “conspiring to raise their prices.”




Tom Price for HHS? The Price Is Wrong!

Tom Price, Trump’s pick to lead Health and Human Services, has an ethically questionable investment and legislative history. Just days after purchasing stock in Zimmer Biomet, for example, he turned around and introduced legislation that would significantly benefit this manufacturer of artificial joint replacements by delaying implementation of a Medicare rule to enhance safety and save taxpayer money. Now Trump wants him to lead the department that regulates companies like Zimmer Biomet as well as overseeing Medicare. Our elders deserve better than this.